Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04410445




Registration number
NCT04410445
Ethics application status
Date submitted
27/05/2020
Date registered
1/06/2020
Date last updated
21/04/2023

Titles & IDs
Public title
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Scientific title
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Secondary ID [1] 0 0
20-214-29/CA045-022
Universal Trial Number (UTN)
Trial acronym
PIVOT-12
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Melanoma Stage III 0 0
Melanoma Stage IV 0 0
Melanoma (Skin) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Bempegaldesleukin
Treatment: Other - Nivolumab

Experimental: Combination of bempegaldesleukin (NKTR-214) + nivolumab - Arm A: Participants will receive bempegaldesleukin (NKTR-214) IV in combination with nivolumab every 3 weeks.

Active comparator: Nivolumab - Arm B: Participants will receive nivolumab IV alone every 4 weeks.


Treatment: Other: Bempegaldesleukin
Specified dose on specified days

Treatment: Other: Nivolumab
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recurrence-free Survival (RFS) by Blinded Independent Central Review (BICR) of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone.
Timepoint [1] 0 0
Up to 21 months
Secondary outcome [1] 0 0
Overall Survival (OS) of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone
Timepoint [1] 0 0
Up to 21 months
Secondary outcome [2] 0 0
Distant Metastasis-Free Survival (DMFS) by Investigator in Patients Who Are Stage III at Study Entry.
Timepoint [2] 0 0
Up to 21 months
Secondary outcome [3] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Timepoint [3] 0 0
Approximately up to 21 months
Secondary outcome [4] 0 0
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire
Timepoint [4] 0 0
From baseline, up to approximately 6 months
Secondary outcome [5] 0 0
Programmed Death-Ligand 1 (PD-L1) Expression as a Predictive Biomarker for Recurrence-free Survival (RFS)
Timepoint [5] 0 0
Up to 21 months
Secondary outcome [6] 0 0
Recurrence-free Survival (RFS) by Investigator of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone.
Timepoint [6] 0 0
Up to 21 months
Secondary outcome [7] 0 0
Time to Disease Progression After the Next Line of Treatment for Study Patients Following Discontinuation of Bempegaldesleukin Plus Nivolumab Versus Nivolumab
Timepoint [7] 0 0
Up to 21 months
Secondary outcome [8] 0 0
Distant Metastasis-Free Survival (DMFS) by Blinded Independent Central Review (BICR) in Patients Who Are Stage III at Study Entry.
Timepoint [8] 0 0
Up to 21 months

Eligibility
Key inclusion criteria
* Male or female patients, age 12 years or older at the time of signing the informed consent form (age 18 years or older where local regulations, countries, and/or institutional policies do not allow for patients < 18 years of age (adolescents) to participate). In regions where adolescents are not allowed to participate in the study due to age restrictions, enrolled patients must be = 18 years of age.
* Histologically confirmed Stage IIIA (LN metastasis > 1 mm), IIIB/C/D, or IV (M1a/b/c/d) cutaneous melanoma by AJCC (8th edition) at study entry that has been completely surgically resected within 12 weeks prior to randomization.
* Tumor tissue available from biopsy or resected disease must be provided to central laboratory for PD-L1 status analysis. Must have PD-L1 expression classification for stratification purposes.
* Disease-free status documented by a complete physical examination and imaging studies within 28 days prior to randomization.
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of ocular/uveal melanoma or mucosal melanoma.
* Active, known or suspected autoimmune disease. Patients with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
* Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
* Prior therapy for melanoma except surgery for the melanoma lesion(s) and/or adjuvant radiation therapy for central nervous system lesions.
* Prior therapy with interferon, talimogene laherparepvec (Imylgic®), interleukin-2 (IL-2) directed therapy, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte-associated protein 4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways).
* Prior malignancy active within the previous 3 years except for locally potentially curable cancers that have been apparently cured.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/07/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
22/09/2022
Sample size
Target
Accrual to date
Final
765
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Cairns Hospital - Cairns
Recruitment hospital [3] 0 0
Icon Cancer Care Wesley - Chermside
Recruitment hospital [4] 0 0
Gallipoli Medical Research Foundation - Greenslopes
Recruitment hospital [5] 0 0
Austin Health - Heidelberg
Recruitment hospital [6] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [7] 0 0
Affinity Clinical Research - Nedlands
Recruitment hospital [8] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [9] 0 0
Melanoma Institute Australia - North Sydney
Recruitment hospital [10] 0 0
Gold Coast University Hospital - Southport
Recruitment hospital [11] 0 0
Tasman Oncology Research - Southport
Recruitment hospital [12] 0 0
Blacktown Hospital - Westmead
Recruitment hospital [13] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
4870 - Cairns
Recruitment postcode(s) [3] 0 0
4032 - Chermside
Recruitment postcode(s) [4] 0 0
4120 - Greenslopes
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment postcode(s) [8] 0 0
2000 - North Sydney
Recruitment postcode(s) [9] 0 0
4215 - Southport
Recruitment postcode(s) [10] 0 0
2145 - Westmead
Recruitment postcode(s) [11] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Montana
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Lienz
Country [31] 0 0
Austria
State/province [31] 0 0
Rankweil
Country [32] 0 0
Austria
State/province [32] 0 0
Salzburg
Country [33] 0 0
Austria
State/province [33] 0 0
St.Pölten
Country [34] 0 0
Austria
State/province [34] 0 0
Vienna
Country [35] 0 0
Czechia
State/province [35] 0 0
Brno
Country [36] 0 0
Czechia
State/province [36] 0 0
Hradec Králové
Country [37] 0 0
Czechia
State/province [37] 0 0
Liberec
Country [38] 0 0
Czechia
State/province [38] 0 0
Olomouc
Country [39] 0 0
Czechia
State/province [39] 0 0
Ostrava Poruba
Country [40] 0 0
Czechia
State/province [40] 0 0
Prague
Country [41] 0 0
Czechia
State/province [41] 0 0
Praha
Country [42] 0 0
France
State/province [42] 0 0
Amiens
Country [43] 0 0
France
State/province [43] 0 0
Angers
Country [44] 0 0
France
State/province [44] 0 0
Bordeau
Country [45] 0 0
France
State/province [45] 0 0
Chambray-lès-Tours
Country [46] 0 0
France
State/province [46] 0 0
Clermont-Ferrand
Country [47] 0 0
France
State/province [47] 0 0
La Tronche
Country [48] 0 0
France
State/province [48] 0 0
Lille
Country [49] 0 0
France
State/province [49] 0 0
Nantes
Country [50] 0 0
France
State/province [50] 0 0
Nice
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Pierre-Bénite
Country [53] 0 0
France
State/province [53] 0 0
Rennes
Country [54] 0 0
France
State/province [54] 0 0
Rouen
Country [55] 0 0
France
State/province [55] 0 0
Saint-Priest-en-Jarez
Country [56] 0 0
France
State/province [56] 0 0
Villejuif
Country [57] 0 0
Germany
State/province [57] 0 0
Berlin
Country [58] 0 0
Germany
State/province [58] 0 0
Bochum
Country [59] 0 0
Germany
State/province [59] 0 0
Buxtehude
Country [60] 0 0
Germany
State/province [60] 0 0
Dresden
Country [61] 0 0
Germany
State/province [61] 0 0
Erfurt
Country [62] 0 0
Germany
State/province [62] 0 0
Essen
Country [63] 0 0
Germany
State/province [63] 0 0
Gera
Country [64] 0 0
Germany
State/province [64] 0 0
Halle
Country [65] 0 0
Germany
State/province [65] 0 0
Hamburg
Country [66] 0 0
Germany
State/province [66] 0 0
Hannover
Country [67] 0 0
Germany
State/province [67] 0 0
Heidelberg
Country [68] 0 0
Germany
State/province [68] 0 0
Heilbronn
Country [69] 0 0
Germany
State/province [69] 0 0
Kiel
Country [70] 0 0
Germany
State/province [70] 0 0
Köln
Country [71] 0 0
Germany
State/province [71] 0 0
Leipzig
Country [72] 0 0
Germany
State/province [72] 0 0
Ludwigshafen
Country [73] 0 0
Germany
State/province [73] 0 0
Magdeburg
Country [74] 0 0
Germany
State/province [74] 0 0
Mannheim
Country [75] 0 0
Germany
State/province [75] 0 0
Münster
Country [76] 0 0
Germany
State/province [76] 0 0
Regensburg
Country [77] 0 0
Germany
State/province [77] 0 0
Schwerin
Country [78] 0 0
Germany
State/province [78] 0 0
Tübingen
Country [79] 0 0
Germany
State/province [79] 0 0
Ulm
Country [80] 0 0
Germany
State/province [80] 0 0
Würzburg
Country [81] 0 0
Greece
State/province [81] 0 0
Ampelokipoi
Country [82] 0 0
Greece
State/province [82] 0 0
Athens
Country [83] 0 0
Greece
State/province [83] 0 0
Heraklion
Country [84] 0 0
Greece
State/province [84] 0 0
Maroúsi
Country [85] 0 0
Greece
State/province [85] 0 0
Pylaía
Country [86] 0 0
Greece
State/province [86] 0 0
Thessaloníki
Country [87] 0 0
Israel
State/province [87] 0 0
Afula
Country [88] 0 0
Israel
State/province [88] 0 0
Be'er Sheva
Country [89] 0 0
Israel
State/province [89] 0 0
Haifa
Country [90] 0 0
Israel
State/province [90] 0 0
Jerusalem
Country [91] 0 0
Israel
State/province [91] 0 0
Petah tikva
Country [92] 0 0
Israel
State/province [92] 0 0
Ramat Gan
Country [93] 0 0
Italy
State/province [93] 0 0
Bari
Country [94] 0 0
Italy
State/province [94] 0 0
Bergamo
Country [95] 0 0
Italy
State/province [95] 0 0
Candiolo
Country [96] 0 0
Italy
State/province [96] 0 0
Genova
Country [97] 0 0
Italy
State/province [97] 0 0
Meldola
Country [98] 0 0
Italy
State/province [98] 0 0
Milano
Country [99] 0 0
Italy
State/province [99] 0 0
Modena
Country [100] 0 0
Italy
State/province [100] 0 0
Napoli
Country [101] 0 0
Italy
State/province [101] 0 0
Padova
Country [102] 0 0
Italy
State/province [102] 0 0
Siena
Country [103] 0 0
Netherlands
State/province [103] 0 0
Amsterdam
Country [104] 0 0
Netherlands
State/province [104] 0 0
Heerlen
Country [105] 0 0
Netherlands
State/province [105] 0 0
Leeuwarden
Country [106] 0 0
Netherlands
State/province [106] 0 0
Leiden
Country [107] 0 0
Netherlands
State/province [107] 0 0
Nijmegen
Country [108] 0 0
Netherlands
State/province [108] 0 0
Utrecht
Country [109] 0 0
Netherlands
State/province [109] 0 0
Veldhoven
Country [110] 0 0
Netherlands
State/province [110] 0 0
Zwolle
Country [111] 0 0
New Zealand
State/province [111] 0 0
Christchurch
Country [112] 0 0
New Zealand
State/province [112] 0 0
Dunedin
Country [113] 0 0
New Zealand
State/province [113] 0 0
Heidelberg
Country [114] 0 0
New Zealand
State/province [114] 0 0
Tauranga
Country [115] 0 0
New Zealand
State/province [115] 0 0
Wellington
Country [116] 0 0
Poland
State/province [116] 0 0
Bialystok
Country [117] 0 0
Poland
State/province [117] 0 0
Bydgoszcz
Country [118] 0 0
Poland
State/province [118] 0 0
Gdansk
Country [119] 0 0
Poland
State/province [119] 0 0
Lublin
Country [120] 0 0
Poland
State/province [120] 0 0
Poznan
Country [121] 0 0
Portugal
State/province [121] 0 0
Coimbra
Country [122] 0 0
Portugal
State/province [122] 0 0
Lisboa
Country [123] 0 0
Portugal
State/province [123] 0 0
Lisbon
Country [124] 0 0
Portugal
State/province [124] 0 0
Porto
Country [125] 0 0
Romania
State/province [125] 0 0
Bucharest
Country [126] 0 0
Romania
State/province [126] 0 0
Cluj-Napoca
Country [127] 0 0
Romania
State/province [127] 0 0
Craiova
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Chelyabinsk
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Krasnodar
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Krasnoyarsk
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Kursk
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Pushkin
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Ryazan'
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Saint Petersburg
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Yaroslavl
Country [136] 0 0
Spain
State/province [136] 0 0
A Coruña
Country [137] 0 0
Spain
State/province [137] 0 0
Badalona
Country [138] 0 0
Spain
State/province [138] 0 0
Barcelona
Country [139] 0 0
Spain
State/province [139] 0 0
Córdoba
Country [140] 0 0
Spain
State/province [140] 0 0
El Palmar
Country [141] 0 0
Spain
State/province [141] 0 0
Jaén
Country [142] 0 0
Spain
State/province [142] 0 0
L'Hospitalet De Llobregat
Country [143] 0 0
Spain
State/province [143] 0 0
Madrid
Country [144] 0 0
Spain
State/province [144] 0 0
Málaga
Country [145] 0 0
Spain
State/province [145] 0 0
Sevilla
Country [146] 0 0
Spain
State/province [146] 0 0
Valencia
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Cambridge
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Cottingham
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Leicester
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Nottingham
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Nektar Therapeutics
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.
Trial website
https://clinicaltrials.gov/study/NCT04410445
Trial related presentations / publications
Eggermont AM, Ascierto PA, Khushalani NI, Schadendorf D, Boland G, Weber J, Lewis KD, Johnson D, Rivalland G, Khattak A, Majem M, Gogas H, Long GV, Currie SL, Chien D, Tagliaferri MA, Carlino MS, Diab A. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncol. 2022 Mar;18(8):903-913. doi: 10.2217/fon-2021-1286. Epub 2022 Jan 25.
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Nektar Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04410445